FDA approves injectable antibiotics for B Braun drug delivery system
Pharmaceutical Technology
APRIL 10, 2025
The FDA has granted approval for the injectable antibiotic, Piperacillin and Tazobactam, to be used in B Braun's drug delivery system.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Pharmaceutical Technology
APRIL 10, 2025
The FDA has granted approval for the injectable antibiotic, Piperacillin and Tazobactam, to be used in B Braun's drug delivery system.
Pharmaceutical Technology
SEPTEMBER 16, 2024
Roche has secured approval from the US Food and Drug Administration for Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 14, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Key innovation: Leading companies in nanoparticles for drug delivery. Bristol-Myers Squibb is the leading patent filer in nanoparticles for drug delivery.
Pharma Mirror
FEBRUARY 18, 2021
Capable of delivering any FDA approved. The post Maculus Therapeutix welcomes Privity FZ LLE and Prepares Capital Raise for Novel Drug Delivery Platform appeared first on Pharma Mirror Magazine. Maculus achieved the breakthrough using a patented novel tunable biodegradable proprietary product, MacuBloc.
Pharmaceutical Technology
APRIL 24, 2023
Covid-19 vaccines from Moderna and Pfizer /BioNTech, which use lipid nanoparticles, became the only two FDA-approved vaccines for almost all ages. However, after a period of slow movement in the field, the FDA approved the first nanodrug, Doxil, for Kaposi sarcoma in 1995.
Fierce Pharma
FEBRUARY 7, 2023
Orexo, leveraging drug delivery tech, seeks FDA approval of nasal high-dose opioid rescue medicine ntaylor Tue, 02/07/2023 - 08:18
XTalks
OCTOBER 27, 2021
Genentech’s ocular implant drug delivery system for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port delivery system into a surgically placed implant in the eye, allowing for continuous delivery of the drug.
XTalks
NOVEMBER 4, 2021
Related: Genentech’s New Ocular Implant Drug Delivery System for Macular Degeneration Could Be a Game Changer. The FDA approval of Vuity exemplifies our continued pursuit of innovative new treatments that push the boundaries of what’s possible in eye care.”. Vuity is available by prescription.
XTalks
JULY 26, 2024
These issues primarily stem from patients and healthcare providers miscalculating or incorrectly administering the drug. Compounded semaglutide products, unlike the US Food and Drug Administration (FDA)-approved ones, can vary widely in strength and packaging, making it easy for mistakes to happen.
Pharmaceutical Technology
APRIL 17, 2023
SNBL chairman and president Dr Ryoichi Nagata said: “We are very pleased to announce that SNBL will be involved in the launch of this novel intranasal drug, which was developed based on SNBL’s novel intranasal drug delivery platform technology, pending potential FDA approval. “We
Pharmaceutical Technology
FEBRUARY 13, 2023
Elyxyb is a prescription nonsteroidal anti-inflammatory drug (NSAID) used for acute migraine treatment in adult patients with or without aura. It is formulated using a self-micro-emulsifying drug delivery system that improves the drug’s bioavailability and solubility.
XTalks
MARCH 21, 2025
The rankings are based on each companys ability to tackle critical challenges from drug delivery and diagnostics to personalized therapies using cutting-edge science. Following Neffys FDA approval , ARS Pharma reported $2.3 Here are 20 companies leading the way in 2025. million in fourth-quarter (Q4) 2024 net revenue.
Outsourcing Pharma
AUGUST 13, 2024
Patients suffering from severe allergic reactions now have access to a new, needle-free treatment option, as the US Food and Drug Administration (FDA) has approved neffy, a 2 mg epinephrine nasal spray developed by ARS Pharmaceuticals, Inc.
Scienmag
JUNE 3, 2022
The repurposing of FDA-approved drugs for alternative diseases is a faster way of bringing new treatments into the clinic. Researchers at Karolinska Institutet in Sweden have repurposed a cancer drug for treatment of neuroinflammatory diseases such as multiple sclerosis.
XTalks
SEPTEMBER 16, 2024
Ocrevus Zunovo uses Halozyme Therapeutics’ Enhanze drug delivery technology , which enhances absorption by temporarily increasing the permeability of the subcutaneous tissue. The enzyme rHuPH20 enables rapid dispersion of the drug into the bloodstream.
Outsourcing Pharma
JULY 23, 2024
Rusan Pharma Private Limited has announced that its active pharmaceutical ingredient (API) manufacturing facility in Ankleshwar, Gujarat, has been granted Good Manufacturing Practice (GMP) approval by the FDA.
XTalks
AUGUST 14, 2024
XTALKS : Changes are Coming to Prefilled Injectable Drug Delivery Systems Live and On-Demand: Thursday, September 12, 2024, at 1pm EDT (10 am PDT) Register for this webinar today to learn more about the future of injectable drug delivery systems and the impact of blow-fill-seal technology.
XTalks
JANUARY 22, 2025
Valneva SE, who developed the worlds first FDA-approved chikungunya vaccine , has now unveiled promising Phase III data for its single-shot chikungunya vaccine, IXCHIQ, in adolescents aged 12 to 17. Following the announcement, Valnevas stock rose by 1.4%.
XTalks
JUNE 14, 2023
XTALKS WEBINAR: Drug Delivery — Evaluating Off-The-Shelf and Novel Drug Delivery Solutions Live and On-Demand: Tuesday, July 11, 2023, at 1pm EDT (10am PDT) Register for this free webinar to learn about important tradeoffs when considering an off-the-shelf (OTS) drug delivery platform vs. novel development.
XTalks
JANUARY 17, 2023
Airsupra is being jointly developed by AstraZeneca and Avillion, also a UK-based drug development company that received funding from. Related: Lung Disease Diagnostic Xenoview Gets FDA Approval for Use with MRI. The FDA approval was based on results from the MANDALA, DENALI and TYREE Phase III studies.
pharmaphorum
NOVEMBER 4, 2020
That includes include France’s Inotrem, which is developing nangibotide in phase 2 testing for septic shock, and Dublin-based Priothera, which is developing immuno-oncology drug mocravimod in phase 2b/3 for acute myeloid leukaemia (AML) in partnership with Kyowa Kirin.
Camargo
OCTOBER 14, 2020
In this situation, the timing and content of amendments following tentative approval can be complicated; Camargo can help sponsors navigate the process. Approval of the Month: FDA Approves First Closed-Loop Monitoring and Drug Delivery Device.
XTalks
NOVEMBER 3, 2021
The team also learned about the FDA approval of Genentech’s new ocular implant drug delivery system, called Susvimo, for the treatment of neovascular, or wet, age-related macular degeneration (nAMD). Read the full articles here: FDA Authorizes Pfizer/BioNTech COVID-19 Vaccine for Kids 5 to 11.
XTalks
AUGUST 30, 2022
One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.
XTalks
MAY 18, 2023
In addition, Resonant Link can charge implants that are as small as 3 mm in diameter and implanted up to 6 cm deep, all while meeting the US Food and Drug Administration (FDA)-mandated temperature limits for implants that prevent surrounding tissues from burning. Our wireless charging for titanium cans changes all of that.”
FDA Law Blog
JUNE 13, 2024
FTC, deep in its foray into the Orange Book, filed an Amicus Brief in the case arguing that the patents do not claim any FDA-approved drug.
pharmaphorum
MARCH 16, 2022
Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca’s top-selling respiratory drug Symbicort, although launch plans remain uncertain for now.
Roots Analysis
FEBRUARY 22, 2022
Autoinjector As Emerging Drug Delivery Device. The generic version of EpiPen received the FDA approval in 2018. Further, given the multidisciplinary requirements of this class of drug delivery devices, several companies have entered into product co-development and co-commercialization agreements as well.
The Pharma Data
OCTOBER 26, 2020
EYSUVIS is the first FDA-approved corticosteroid specifically for dry eye disease treatment. Kala’s proprietary AMPPLIFY drug delivery technology is what gets EYSUVIS its backstage pass to penetrate the mucus barrier and delivering the loteprednol etabonate (LE) to the ocular tissue. INVELTYS launched in the U.S.
Delveinsight
NOVEMBER 26, 2020
Fortunately, there are FDA-approved products present in the Retinal vision occlusion drug market including Lucentis (ranibizumab), Eylea (aflibercept), and Ozurdex (dexamethasone intravitreal implant) with Avastin in use as an off-label therapy to help manage the condition and improve the vision.
XTalks
JUNE 11, 2024
Drug-eluting stents (DES): DES reduce the incidence of restenosis and are coated with drugs that inhibit scar tissue growth. DCBs: DCBs, such as the Agent DCB, combine mechanical widening of the artery with drug delivery to the vessel wall to prevent cell proliferation.
FDA Law Blog
SEPTEMBER 19, 2023
The FTC expressed concern that patent listings that do not meet the statutory criteria undermine the competitive process, may disincentivize investment in developing generic and follow-on products, and reduce patient access to more affordable drugs thereby increasing costs to the healthcare system.
pharmaphorum
NOVEMBER 7, 2022
The conference will explore advancements in ophthalmic treatments and variety of novel drugs, which are showing great clinical trial data. There will also be a specific focus on drug delivery along with advancements in novel technologies.
XTalks
MAY 30, 2024
This innovative formulation uses Halozyme’s Enhanze drug delivery technology, facilitating the subcutaneous administration of biologics. New CIDP Treatments on the Market In January 2024, the FDA approved Takeda’s Gammagard Liquid for the treatment of CIDP in adults.
Delveinsight
NOVEMBER 29, 2020
Looking at the potential of the pipeline therapies they hold once approved, pharmaceutical companies are charting out a seemingly exciting course in the market. Therapies such as dexamethasone drug delivery system and vascular endothelial growth factor inhibitors have already pierced deeper into the market.
The Pharma Data
JANUARY 17, 2021
“This marks another significant milestone as we continue to leverage our polypeptide nano-particle technology for siRNA drug delivery to advance our pipeline of oncology therapeutic candidates,” said Patrick Lu , Ph.D., the founder, President and CEO of Sirnaomics. Chief Medical Officer.
FDA Law Blog
MARCH 12, 2024
It’s difficult to conclude from these statements, as FTC and Congress appear to have, that device patents categorically shouldn’t be listed in the Orange Book.
The Pharma Data
JANUARY 6, 2021
Standard antibodies cannot access toxin already inside neurons, and thus BAT® (Botulism AntiToxin, a product of Emergent BioSolutions), the only FDA-approved antitoxin, is only effective while the toxin remains in the circulation.
The Pharma Data
JANUARY 17, 2021
Food and Drug Administration (FDA) approved Janssen Pharmaceuticals ’ (a Johnson and Johnson company) Darzalex Faspro for adults with newly diagnosed light chain amyloidosis. It was approved in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd). Michael Vi/Shutterstock.
XTalks
NOVEMBER 5, 2024
Additionally, a collaboration with NurExone is creating an intranasal delivery system for exosome-based therapies targeting spinal cord injuries, with potential expansion into other neurological uses. Polyrizon’s focus on intranasal protection aligns with a rapidly expanding market in drug delivery innovation.
XTalks
JANUARY 18, 2023
Ayesha also talked about the FDA approval of AstraZeneca’s asthma inhaler Airsupra, the first-in-class drug that contains both a beta agonist and corticosteroid. The inhaler is approved as a rescue medication for adults with asthma to help treat bronchoconstriction and asthma attacks.
pharmaphorum
JUNE 22, 2021
GlaxoSmithKline (GSK) has reported encouraging data for its COVID-19 antibody sotrovimab, and an alliance with Halozyme to develop a new generation of long-acting HIV drugs, as it prepares to give a much-anticipated update to shareholders tomorrow.
The Pharma Data
AUGUST 31, 2021
Additionally, Janssen will present an update on the Phase 3 SunRISe-2 trial evaluating an investigational intravesical drug delivery system, TAR-200, in combination with the programmed cell death receptor-1 (PD-1) inhibitor cetrelimab in muscle-invasive urothelial carcinoma (Abstract # MP13-17). [1]. 2] ERLEADA ® received U.S.
The Pharma Data
JANUARY 15, 2021
Food and Drug Administration (FDA) approval of Darzalex Faspro ® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] Haematologica.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content